Birk Poller

1.7k total citations
35 papers, 1.3k citations indexed

About

Birk Poller is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Birk Poller has authored 35 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 15 papers in Pharmacology and 13 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Birk Poller's work include Drug Transport and Resistance Mechanisms (23 papers), Pharmacological Effects and Toxicity Studies (12 papers) and Pharmacogenetics and Drug Metabolism (11 papers). Birk Poller is often cited by papers focused on Drug Transport and Resistance Mechanisms (23 papers), Pharmacological Effects and Toxicity Studies (12 papers) and Pharmacogenetics and Drug Metabolism (11 papers). Birk Poller collaborates with scholars based in Switzerland, United States and Netherlands. Birk Poller's co-authors include Jörg Huwyler, Jürgen Drewe, Heike Gutmann, Gian Camenisch, Stephan Krähenbühl, Alfred H. Schinkel, Annett Kunze, Seng Chuan Tang, Jos H. Beijnen and Els Wagenaar and has published in prestigious journals such as American Journal of Clinical Nutrition, Brain Research and Journal of Neurochemistry.

In The Last Decade

Birk Poller

35 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Birk Poller Switzerland 20 684 337 257 254 172 35 1.3k
Jocelyn Yabut United States 16 471 0.7× 357 1.1× 273 1.1× 314 1.2× 86 0.5× 19 1.3k
Bill J. Smith United States 20 697 1.0× 467 1.4× 327 1.3× 348 1.4× 157 0.9× 28 1.6k
Guangqing Xiao United States 20 555 0.8× 386 1.1× 308 1.2× 262 1.0× 47 0.3× 28 1.2k
J. Cory Kalvass United States 22 1.2k 1.7× 445 1.3× 651 2.5× 466 1.8× 123 0.7× 34 1.9k
Lu-Bin Lan United States 16 1.1k 1.7× 746 2.2× 379 1.5× 549 2.2× 110 0.6× 19 2.0k
Geri A. Sawada United States 21 504 0.7× 489 1.5× 129 0.5× 75 0.3× 147 0.9× 37 1.4k
Julie Jodoin Canada 16 581 0.8× 685 2.0× 184 0.7× 113 0.4× 229 1.3× 19 1.6k
Lindsey O. Webster United States 11 1.0k 1.5× 398 1.2× 555 2.2× 321 1.3× 48 0.3× 14 1.7k
Rujia Xie United States 16 659 1.0× 384 1.1× 300 1.2× 235 0.9× 25 0.1× 32 1.2k
Yoshitane Nozaki Japan 16 902 1.3× 193 0.6× 497 1.9× 336 1.3× 38 0.2× 26 1.3k

Countries citing papers authored by Birk Poller

Since Specialization
Citations

This map shows the geographic impact of Birk Poller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birk Poller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birk Poller more than expected).

Fields of papers citing papers by Birk Poller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birk Poller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birk Poller. The network helps show where Birk Poller may publish in the future.

Co-authorship network of co-authors of Birk Poller

This figure shows the co-authorship network connecting the top 25 collaborators of Birk Poller. A scholar is included among the top collaborators of Birk Poller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birk Poller. Birk Poller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Amirabadi, Hossein Eslami, Joanne M. Donkers, Markus Walles, et al.. (2024). Intestinal Cells-on-Chip for Permeability Studies. Micromachines. 15(12). 1464–1464. 1 indexed citations
2.
Loesche, Christian, D Picard, Gebhard Thoma, et al.. (2024). LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clinical and Translational Science. 17(2). e13724–e13724. 2 indexed citations
3.
Rodríguez-Pérez, Raquel, Birk Poller, Felix Huth, et al.. (2024). Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms. Archives of Toxicology. 99(1). 377–391. 2 indexed citations
4.
Huth, Felix, et al.. (2024). Improving In Vitro–In Vivo Extrapolation of Clearance Using Rat Liver Microsomes for Highly Plasma Protein-Bound Molecules. Drug Metabolism and Disposition. 52(5). 345–354. 2 indexed citations
5.
Rodríguez-Pérez, Raquel, Birk Poller, Felix Huth, et al.. (2024). Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC). Archives of Toxicology. 98(10). 3409–3424. 2 indexed citations
6.
Kulmatycki, Kenneth, et al.. (2023). Absorption, Distribution, Metabolism, and Excretion of [14C]iptacopan in Healthy Male Volunteers and in In Vivo and In Vitro Studies. Drug Metabolism and Disposition. 51(7). 873–883. 12 indexed citations
7.
Huth, Felix, et al.. (2021). Predicting Oral Absorption for Compounds Outside the Rule of Five Property Space. Journal of Pharmaceutical Sciences. 110(6). 2562–2569. 19 indexed citations
8.
Umehara, Kenichi, et al.. (2019). Examining P-gp efflux kinetics guided by the BDDCS – Rational selection of in vitro assay designs and mathematical models. European Journal of Pharmaceutical Sciences. 132. 132–141. 8 indexed citations
9.
Poller, Birk, Ralph Woessner, Avantika Barve, et al.. (2019). Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Pulmonary Pharmacology & Therapeutics. 57. 101809–101809. 8 indexed citations
10.
Poller, Birk, et al.. (2016). New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data. European Journal of Pharmaceutical Sciences. 86. 96–102. 13 indexed citations
11.
Kunze, Annett, Birk Poller, Jörg Huwyler, & Gian Camenisch. (2015). Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins. Drug Metabolism and Personalized Therapy. 30(3). 175–188. 24 indexed citations
12.
Kunze, Annett, Jörg Huwyler, Birk Poller, Heike Gutmann, & Gian Camenisch. (2014). In Vitro–In Vivo Extrapolation Method to Predict Human Renal Clearance of Drugs. Journal of Pharmaceutical Sciences. 103(3). 994–1001. 33 indexed citations
13.
Tang, Seng Chuan, Nienke A. G. Lankheet, Birk Poller, et al.. (2012). P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib. Journal of Pharmacology and Experimental Therapeutics. 341(1). 164–173. 33 indexed citations
14.
Tang, Seng Chuan, Jurjen S. Lagas, Nienke A. G. Lankheet, et al.. (2011). Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. International Journal of Cancer. 130(1). 223–233. 129 indexed citations
15.
Poller, Birk, Dilek Iusuf, Rolf W. Sparidans, et al.. (2011). Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics. Drug Metabolism and Disposition. 39(5). 729–735. 58 indexed citations
16.
Fasler‐Kan, Elizaveta, Claudia Suenderhauf, Natasha S. Barteneva, et al.. (2010). Cytokine signaling in the human brain capillary endothelial cell line hCMEC/D3. Brain Research. 1354. 15–22. 28 indexed citations
17.
Steinert, Robert E., Birk Poller, Mariacristina Castelli, et al.. (2009). Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects. Clinical Pharmacology & Therapeutics. 86(6). 644–650. 39 indexed citations
18.
Beglinger, Christoph, et al.. (2008). Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects. Clinical Pharmacology & Therapeutics. 84(4). 468–474. 45 indexed citations
19.
Poller, Birk, Heike Gutmann, Stephan Krähenbühl, et al.. (2008). The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies. Journal of Neurochemistry. 107(5). 1358–1368. 262 indexed citations
20.
Gutmann, Heike, et al.. (2006). Hypericum perforatum: Which Constituents may Induce Intestinal MDR1 and CYP3A4 mRNA Expression?. Planta Medica. 72(8). 685–690. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jocelyn Yabut Breakdown of academic impact, for papers by Bill J. Smith Breakdown of academic impact, for papers by Guangqing Xiao Breakdown of academic impact, for papers by J. Cory Kalvass Breakdown of academic impact, for papers by Lu-Bin Lan Breakdown of academic impact, for papers by Geri A. Sawada Breakdown of academic impact, for papers by Julie Jodoin Breakdown of academic impact, for papers by Lindsey O. Webster Breakdown of academic impact, for papers by Rujia Xie Breakdown of academic impact, for papers by Yoshitane Nozaki
Rankless by CCL
2026